|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Mexiletine#Use in Specific Populations]] |
| {{Mexiletine}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Use in Specific Populations==
| |
| | |
| ===Pregnancy===
| |
| | |
| ===Teratogenic Effects===
| |
| | |
| ===Pregnancy category C===
| |
| | |
| Reproduction studies performed with mexiletine in rats, mice and rabbits at doses up to four times the maximum human oral dose (24 mg/kg in a 50 kg patient) revealed no evidence of teratogenicity or impaired fertility but did show an increase in fetal resorption. There are no adequate and well-controlled studies in pregnant women; this drug should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.
| |
| | |
| ===Nursing Mothers===
| |
| | |
| Mexiletine appears in human milk in concentrations similar to those observed in plasma. Therefore, if the use of mexiletine hydrochloride is deemed essential, an alternative method of infant feeding should be considered.
| |
| | |
| ===Pediatric Use===
| |
| | |
| Safety and effectiveness in pediatric patients have not been established.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MEXILETINE HYDROCHLORIDE CAPSULE [TEVA PHARMACEUTICALS USA INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=693da40b-26d4-40d6-87d1-158e256f40ab | publisher = | date = | accessdate = 3 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{Antiarrhythmic agents}}
| |
| | |
| [[Category:Sodium channel blockers]]
| |
| [[Category:Phenol ethers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |